Liver/Biliary Disorders News

Women with intrahepatic cholestasis of pregnancy delivered earlier and had a lower percentage of stillbirths compared with women without the liver disorder, researchers reported in the American Journal of Obstetrics & Gynecology.

Higher intake of total and dairy protein and lower animal protein consumption correlated with a reduced risk for mortality among patients with cirrhosis, according to data published in BMC Gastroenterology.

A familial risk score comprised of age, obesity, type 2 diabetes and family history of nonalcoholic fatty liver disease accurately identified advanced fibrosis among first-degree relatives, according to researchers.

After 3 months of treatment, seladelpar significantly improved pruritus and markers of liver injury compared with placebo in patients with primary biliary cholangitis, CymaBay Therapeutics recently announced.

Disparities in receipt of liver transplantation and mortality persisted over time among hospitalized Black and Hispanic patients with decompensated cirrhosis compared with their white counterparts, according to data in JAMA Network Open.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.

Among patients with nonalcoholic steatohepatitis in the United States, 20% progressed to cirrhosis within 4 years, with female sex and nonsmoking status linked to lower risk for progression, according to data from the TARGET-NASH trial.

EASL Congress 2023 has ended but, as the society’s official media partner, Healio was at the forefront covering the latest in liver disease. Wondering what you may have missed? Healio recaps the biggest news disrupting the specialty.

Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data presented at EASL Congress.

Research demonstrated that hepatocellular carcinoma surveillance is cost-effective at a lower incidence threshold of 0.7% in virologically cured patients with hepatitis C virus, underscoring the need to update clinical guidelines.